BROAD AGENCY ANNOUNCEMENT - BIOMEDICAL RESEARCH AND DIVING EQUIPMENT DEVELOPMENT
Key Takeaways
- 33 days until response deadline
- Full and open competition - all businesses eligible to bid
- Work to be performed in WASHINGTON NAVY YARD, DC
- Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Contract Details
- Notice ID
- N0002425R4305
- Opportunity Type
- Sources Sought
- Agency
- DEPT OF DEFENSE
- Sub-Agency
- DEPT OF THE NAVY
- Office
- NAVSEA HQ
- Posted Date
- Monday, October 7, 2024
- Response Deadline
- Saturday, February 28, 2026
- Set-Aside
- Full & Open Competition
- Place of Performance
- WASHINGTON NAVY YARD, DC, 20376-5000
- Status
- Active
Description
Broad Agency Announcement (BAA) for BAA-25-G-01 BIOMEDICAL RESEARCH AND DIVING EQUIPMENT DEVELOPMENT IN THE AREAS OF DIVER HEALTH, SAFETY, AND EFFECTIVENESS, AS WELL AS SUBMARINER SURVIVABILITY IN A DISABLED SUBMARINE Naval Sea Systems Command (NAVSEA) is soliciting pre-proposals and full proposals for applied Biomedical Research and Diving Equipment Development with a focus on Diver Health, Safety, and Performance, Deep Diving Advancements, and Submarine Escape and Rescue. The programs goals are presented in detail below. It is the intent that this Broad Agency Announcement (BAA) be open for a two-year period from the date of publication. Specified dates are given in paragraph 2.a. below for submission of pre-proposals and full proposals to be awarded within Fiscal Year (FY) 2026 and 2027
Why This Opportunity Matters
The Department of DEFENSE is conducting market research to identify potential sources for research and development in biotechnology (except nanobiotechnology) in WASHINGTON NAVY YARD, DC. Responding to this notice helps ensure your company is considered for the eventual solicitation.
Similar Opportunities
AJ11-VA Depleted Uranium Program PO 512C50314
Q-RNAscope In-House Assay
Low-cost, Connected, Digital Lateral Flow Platform to Detect Influenza A, Influenza B, and SARS-Cov -2 for use in Over-the-Counter (OTC) Settings
A-High Throughput Transcriptomics (HTTr)
human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
